<description>&lt;p class="MsoNormal" style="margin: 12.0pt 0in 12.0pt 0in;"&gt; &lt;span lang="EN" xml:lang="EN"&gt;In this episode of &lt;em style= "mso-bidi-font-style: normal;"&gt;Hot Topics&lt;/em&gt;, Dr. Nicholas Morris interviews &lt;strong&gt;&lt;u&gt;&lt;span style="color: #1155cc;"&gt;&lt;a href= "https://fr.linkedin.com/in/claire-dahyot-fizelier-10272822b/en?trk=public_post_feed-actor-name"&gt; Claire Dahyot-Fizelier, M.D,&lt;/a&gt;&lt;/span&gt;&lt;/u&gt; &lt;u&gt;&lt;span style= "color: #1155cc;"&gt;&lt;a href= "https://fr.linkedin.com/in/claire-dahyot-fizelier-10272822b/en?trk=public_post_feed-actor-name"&gt; Ph.D.&lt;/a&gt;&lt;/span&gt;&lt;/u&gt;&lt;/strong&gt;&lt;strong style= "mso-bidi-font-weight: normal;"&gt;&lt;u&gt;&lt;span style= "color: #1155cc;"&gt;&lt;a href= "https://fr.linkedin.com/in/claire-dahyot-fizelier-10272822b/en?trk=public_post_feed-actor-name"&gt;&lt;span style="font-weight: normal;"&gt;,&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/u&gt;&lt;/strong&gt; a professor of anesthesia and intensive care at the University of Poitiers, to explore the groundbreaking PROPHY-VAP trial published in &lt;em style="mso-bidi-font-style: normal;"&gt;The Lancet Respiratory Medicine&lt;/em&gt;. This landmark study investigates the impact of single-dose ceftriaxone prophylaxis on ventilator-associated pneumonia (VAP) in acute brain injury patients. Dr. Dahyot-Fizelier discusses the rationale behind the study, key findings and the broader implications for ICU practices. Tune in to discover how this trial could reshape approaches to infection prevention and improve patient outcomes in neurocritical care.&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal" style="margin: 12.0pt 0in 12.0pt 0in;"&gt; &lt;span lang="EN" xml:lang="EN"&gt;Show notes:&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal" style="margin: 12.0pt 0in 12.0pt .5in;"&gt; &lt;span lang="EN" xml:lang="EN"&gt;&lt;a href= "https://doi.org/10.1016/S2213-2600(23)00471-X"&gt;&lt;span style= "color: #1155cc;"&gt;https://doi.org/10.1016/S2213-2600(23)00471-X&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal" style="margin: 12.0pt 0in 12.0pt .5in;"&gt; &lt;span lang="EN" xml:lang="EN"&gt;Dahyot-Fizelier C, Lasocki S, Kerforne T, Perrigault PF, Geeraerts T, Asehnoune K, Cinotti R, Launey Y, Cottenceau V, Laffon M, Gaillard T, Boisson M, Aleyrat C, Frasca D, Mimoz O, on behalf of the PROPHY-VAP Study Group and the ATLANREA Study Group. Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial. &lt;em&gt;The Lancet Respiratory Medicine&lt;/em&gt;. 2024 May 1;12(5):375-85.&lt;/span&gt;&lt;/p&gt;</description>

Neurocritical Care Society Podcast

Neurocritical Care Society

HOT TOPICS: The PROPHY-VAP Study

DEC 3, 202437 MIN
Neurocritical Care Society Podcast

HOT TOPICS: The PROPHY-VAP Study

DEC 3, 202437 MIN

Description

In this episode of Hot Topics, Dr. Nicholas Morris interviews Claire Dahyot-Fizelier, M.D, Ph.D., a professor of anesthesia and intensive care at the University of Poitiers, to explore the groundbreaking PROPHY-VAP trial published in The Lancet Respiratory Medicine. This landmark study investigates the impact of single-dose ceftriaxone prophylaxis on ventilator-associated pneumonia (VAP) in acute brain injury patients. Dr. Dahyot-Fizelier discusses the rationale behind the study, key findings and the broader implications for ICU practices. Tune in to discover how this trial could reshape approaches to infection prevention and improve patient outcomes in neurocritical care.

Show notes:

https://doi.org/10.1016/S2213-2600(23)00471-X

Dahyot-Fizelier C, Lasocki S, Kerforne T, Perrigault PF, Geeraerts T, Asehnoune K, Cinotti R, Launey Y, Cottenceau V, Laffon M, Gaillard T, Boisson M, Aleyrat C, Frasca D, Mimoz O, on behalf of the PROPHY-VAP Study Group and the ATLANREA Study Group. Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial. The Lancet Respiratory Medicine. 2024 May 1;12(5):375-85.